Bolt Biotherapeutics completed its acquisition of Prana Therapies on 23 October 2026, but a separate US$120 million financing was still described as awaiting closing in the official documents reviewed for this report. The scheduled financing date is 26 October, subject to conditions. That is not confirmation that Bolt has received the money.
Two transactions, different completion status
The issuer’s Form 8-K records the acquisition as completed. Bolt separately signed a private placement: a sale of securities to selected investors rather than an IPO open to retail applications.
| Item | Verified position and primary record |
|---|---|
| Acquisition | Completed 23 October 2026. 8-K, Item 2.01. |
| Financing | US$120 million gross; expected closing 26 October, subject to conditions. 8-K, Item 1.01. |
| Warrants | About US$60 million if fully exercised for cash; not assured. 8-K, financing terms. |
| Conversion | Non-voting convertible preferred shares; common-share conversion requires stockholder approval and is subject to limits. Purchase agreement. |
A warrant gives its holder the right to purchase securities under specified terms. The potential warrant cash is therefore not money already raised. Gross proceeds are also not the same as net cash after transaction costs.
Research plans remain forecasts
In its 23 October announcement, Bolt said it would focus on Prana’s antibody pipeline, led by PRA-216. The programme is in Phase 2 development for asthma, chronic obstructive pulmonary disease and atopic dermatitis; another Phase 2 study is planned. This report does not establish regulatory approval or treatment effectiveness.
The company expects the financing to support operations into 2028. That is a management forecast, not a guaranteed cash runway. Shareholders should distinguish the completed acquisition from the financing close, future warrant exercise and research milestones.
What to watch next
Look for an official closing confirmation and subsequent stockholder materials. No share-price reaction, investment return or measured trending rank has been verified here. For a separate funding structure, see CapKet’s report on Arcus’s completed public share offering.
Primary records checked at (UTC). The announcement and transaction dates above remain 23 October; this source-check time does not turn them into new events.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.